Claims for Patent: 5,290,773

Summary for Patent: 5,290,773

Title:	Sulfonyl derivatives
Abstract:	A sulfonyl compound of the formula ##STR1## The above illuminated formula (I) undergo bimolecular condensation by the condensing agents and easily form simple metal salts especially metal complexes which act as combatting viruses and inhibiting tissue growth.
Inventor(s):	Takayanagi; Takeo (Yonkers, NY)
Assignee:
Application Number:	07/497,508
Patent Claims:	1. A complex or sulfonyl compound of the formula ##STR29## wherein R and R' are individually selected from the group consisting of hydrogen, --COCHR.sub.4, --COC(R.sub.4).sub.3, --SO.sub.2 CH.sub.3, --COOCH.sub.2 CH.sub.3, --CH.sub.2 CH.sub.2 --R.sub.4, --CH.sub.2 --CH.sub.2 OH, --CONH--CH.sub.2 CH.sub.2 R.sub.4, --CONHCH.sub.2 COOCH.sub.2 CH.sub.3, --CH.sub.2 CH.sub.2 OCONH.sub.2, R.sub.4 is a member selected from the group consisting of Cl, ##STR30## --NHCOCH.sub.2 CH.sub.2 OH, Mt is magnesium wherein ##STR31## can be changeable to an alkyl, halogen or an aminomethyl, R.sup.1 and R.sup.2 are selected from the group consisting of ##STR32## 6-mercaptopurinyl, 5-fluorouracilyl, prednisolyl, salicylhydrazidyl, 1-allyl-2-thioracilyl, hydroxylamine, isamidyl or R.sub.1 and R.sub.2 are selected from the group consisting of --O--CH.sub.3, --O--CH.sub.2 CH.sub.3, --O--CH.sub.2 --CH:CH.sub.2, --O--C.sub.6 H.sub.5 or Benzhydrol, or R.sup.1 and R.sup.2 is an ether selected from the ether group consisting of ClCH.sub.2 OCH.sub.2 Cl CH.sub.3 OCH.sub.2 CH.sub.2 OCH.sub.3 CH.sub.2 ClCH.sub.2 OCH.sub.2 CH.sub.2 Cl C.sub.4 H.sub.9 OCH.sub.3 (C.sub.6 H.sub.5).sub.2 O CH.sub.3 --O--CHCl.sub.2, (CH.sub.2 .dbd.CHCH.sub.2).sub.2 O CH.sub.2 .dbd.CHOCH.dbd.CH.sub.2 C.sub.4 H.sub.9 OC.sub.4 H.sub.9 C.sub.6 H.sub.5 OCH.sub.3 ClCH.sub.2 --OC.sub.2 H.sub.5, OHCH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 Cl, ClCH.sub.2 CHCl--OC.sub.2 H.sub.5 ##STR33## or R.sup.1 and R.sup.2 are an inorganic group selected from the group consisting of --(Na)SH, --(K)F, --(K)I, --C--Cl.sub.3 with a condensing agent. 2. A metal complex of a compound of claim 1 including antitumor agent selected from the group consisting of nitrogen mustard, cyclophosphoamide, thyothepa, 6-mercaptopurine, 5-fluorouracil, vinblastine, L-asparaginase, carbamate and chloroethyl. 3. A metal complex of a compound of claim 1 including antibiotic selected from the group consisting of chloramphenicol and penicillin. 4. A metal complex of a compound of claim 1 including curvative organic pigment selected from the group consisting of pyoktanin (methyl violet), methylene blue and acriflavin. 5. A metal complex of a compound of claim 1 including organic compound selected from the group consisting of 1-allyl-2-thiourea, N-methylformamide, abscisis acid, quinonimine, saliylic acid methyl ester, d-maleic acid chloropheniramine, salicyl hydrazide, glucoside and cholchicine. 6. A metal complex of a compound of claim 1 including ferment selected from the group consisting of hyaluronidase, lysozyme chloride, collagenase, diastase and metal fixed ferment. 7. A metal complex of a compound of claim 1 including hormone selected from the group consisting of androgen, adrenocortical hormone and estrogen. 8. A metal complex of a compound of claim 1 including quinone compound selected from the group consisting of (Tetra-2(chlorethyl)amino-o-quinone (Tetra(N-methyl-N-formyl)amino)-o-quinone (Tetra(N-carboethoxy)amino)-o-quinone (Tetra(N-aziridino))-o-quinone (Tetra(N-methyl-N-hydroxyl)amino)-O-quinone. 9. A metal complex of a compound of claim 1 including nitroso compound selected from the group consisting of ##STR34## 10. A metal complex of a compound of claim 1 including carbamate selected from the group consisting of ##STR35## 11. A metal complex of a compound of claim 1 including 2-chloro-ethyl derivative selected from the group consisting of ##STR36## 12. A composition for treating cancer comprising an amount of a complex of claim 1 sufficient to treat cancer and an inert pharmaceutical carrier.

Details for Patent 5,290,773

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2039-02-26
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2039-02-26
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2039-02-26
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2039-02-26
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26